Australia: Australian Vioxx litigation finally resolved

Last Updated: 9 March 2015
Article by Toby Biddle

On 26 February 2015, Justice Jessup of the Australian Federal Court approved a settlement which brought to end the long-running representative (class) action brought on behalf of consumers of the arthritis drug, Vioxx. The settlement approval follows an earlier judgment of Justice Jessup in 2013, in which he had refused to approve a settlement.

The case has had significant implications for product liability class actions, especially actions involving pharmaceuticals and medical devices. In particular, the Vioxx litigation has highlighted the difficulties in prosecuting healthcare product liability cases as class actions given the importance of varying individual patient factors, notably on issue concerning causation of damages.

This article looks at the key aspects of the decision and provides commentary on the implications for life sciences companies and insurers which cover product risks.

History of proceedings

Vioxx was alleged to have caused adverse cardiovascular side-effects in several arthritis patients.

One such patient, Graeme Peterson, was the lead applicant in Federal Court proceedings brought on behalf of Vioxx consumers. In March 2010 Peterson was awarded damages against the supplier of Vioxx by Jessup J on the basis of a finding that a myocardial infarction (heart attack) suffered by Peterson was caused by Vioxx. Jessup J also made a number of findings on issues common to the remainder of the class.

In October 2011 the Full Court of the Federal Court allowed an appeal against the judgment for Peterson and in May 2012 the High Court refused special leave. This resolved the individual claim of Peterson but did not resolve the claims of other group members of the proceedings (being other patients who alleged they had taken Vioxx and consequently suffered adverse cardiovascular effects).

In April 2013 Peterson (through his lawyers, Slater & Gordon) brought an application in the Federal Court for approval of a settlement agreement to resolve the claims of the remaining group members. Under the Federal Court of Australia Act 1976, a representative proceeding can only be settled with the approval of the Court.

The proposed settlement agreement involved establishment of a scheme by which group members needed to satisfy two sets of criteria, the first being a diagnosis of myocardial infarction, and the second being proof of use of Vioxx within a certain number of days prior to the myocardial infarction taking place. Satisfaction of the criteria would entitle group members to a share of the settlement. The settlement was capped at total payments by the respondents for the entire class of living group members of $497,500 and for the entire class of deceased group members of $45,000. A total of 1660 group members of Peterson's proceedings had registered their intentions to advance individual claims. The settlement also involved the respondents abandoning their claim for costs against Peterson arising from the trial and the appeals.

On 20 May 2013 Jessup J declined to approve the settlement. Among other things, Jessup J took issue with the fact that the settlement made no discrimination between group members who had risk factors for myocardial infarction other than Vioxx consumption, and group members who might have had no other risk factors (one of the issues in Peterson's case was that he had risk factors other than Vioxx use). Jessup J also expressed misgivings concerning a potential conflict if the lead applicant's lawyers, Slater & Gordon, would have an ongoing role in determining whether group members satisfied eligibility criteria.

Modified settlement agreement and its approval

In November 2014 the parties put forward a modified version of the settlement agreement for approval by the Court.

In his judgment on this application, Jessup J indicated that he considered the amount of the settlement (which was unchanged from the previous version) to be small – he noted the maximum any individual group member would receive would be $4,629.36. However, he considered that the amendments had addressed his concern about the lack of discrimination among patients with different circumstances. From the judgment, this appears to have been done though the introduction into the settlement agreement of a points system, recognising different circumstances of different group members and damages being allocated accordingly.

Jessup J was also satisfied on the issue of conflict of interest of the lead applicant's lawyers having a role going forward in determining which patients qualified. This was because the relevant determinations had now taken place and were part of the settlement being submitted for approval.

Even with these issues addressed, Jessup J expressed ongoing concern with the settlement and made a comment suggesting he had anticipated that individual cases of group members other than Peterson may have been brought forward to be tested against the answers to the common issues (noting that Peterson's individual claim had failed largely on individual causation issues).

Despite these concerns, Jessup J noted the following considerations which favoured the approval of the settlement:

  • All group members had been informed of the terms of the proposed settlement and there had been very few objections. The objections which were made were not sufficient to stand in the way of approval of the settlement.
  • No group member had applied to step forward to replace Peterson as the lead applicant. Jessup J commented that he did not see why Peterson, having run the case in the interests of other group members but having failed in his individual claim, should continue to be exposed to risk "in the interests of others who are content to remain below the parapet".
  • The applicants could not be compelled to prosecute the case. If the proceedings were not resolved and were not prosecuted, the result would be that sooner or later the proceedings would be dismissed, meaning group members would get nothing and the lead applicant would still be faced with substantial costs orders.

Conclusion

The approval of the settlement finally brings to a close an action which has been before the Australian courts for the best part of decade.

Both the substantive action in Vioxx and the settlement applications highlight many of the difficulties in prosecuting product liability claims as class actions. In particular, individual causation issues are frequently at play, meaning that neither the parties, nor the court, can have absolute confidence that the finding on causation in a lead applicant's case is likely to be replicated in the cases of all group members.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions